Search research articles
Contact Us
Filters
Showing results (191-200 of 225) with videos related to
Page
of 23
Sort By:
NPJ Vaccines
|
October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Tommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
Susanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
The Journal of Infection
|
June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Eimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Clinical and Experimental Immunology
|
February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Lancet (London, England)
|
August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Iscience
|
December 13, 2023
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Helen Ratcliffe, Karen S Tiley, Stephanie Longet, et al.
The Pediatric Infectious Disease Journal
|
July 16, 2019
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine
Jasur Danier, Luis Rivera, Carine Claeys, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme
Jeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
The Pediatric Infectious Disease Journal
|
November 15, 2019
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial
Ghassan Dbaibo, Arshad Amanullah, Carine Claeys, et al.
The Lancet. Respiratory Medicine
|
June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Robert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 225) with videos related to
Sort By:
Page
of 23
NPJ Vaccines
|
October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Tommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
Susanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
The Journal of Infection
|
June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Eimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Clinical and Experimental Immunology
|
February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Lancet (London, England)
|
August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Iscience
|
December 13, 2023
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Helen Ratcliffe, Karen S Tiley, Stephanie Longet, et al.
The Pediatric Infectious Disease Journal
|
July 16, 2019
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine
Jasur Danier, Luis Rivera, Carine Claeys, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme
Jeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
The Pediatric Infectious Disease Journal
|
November 15, 2019
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial
Ghassan Dbaibo, Arshad Amanullah, Carine Claeys, et al.
The Lancet. Respiratory Medicine
|
June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Robert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
Page
of 23